VACCINEX, INC. financial data

Symbol
VCNX on OTC
Location
Rochester, NY
Fiscal year end
31 December
Latest financial report
10-K - Q4 2024 - 15 Apr 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 79% % 12%
Return On Equity 1855% % -3.7%
Return On Assets -434% % 24%
Operating Margin -3117% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2,676,637 shares 117%
Common Stock, Shares, Outstanding 2,676,637 shares 200%
Entity Public Float $5,577,428 USD -46%
Common Stock, Value, Issued $1,000 USD
Weighted Average Number of Shares Outstanding, Basic 2,098,947 shares 353%
Weighted Average Number of Shares Outstanding, Diluted 2,098,947 shares 353%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $601,000 USD
Research and Development Expense $12,545,000 USD -24%
General and Administrative Expense $6,791,000 USD -1.3%
Costs and Expenses $19,336,000 USD -18%
Operating Income (Loss) $18,735,000 USD 18%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $18,634,000 USD 8%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $18,634,000 USD 8%
Earnings Per Share, Basic -9 USD/shares 80%
Earnings Per Share, Diluted -9 USD/shares 80%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $1,107,000 USD -28%
Accounts Receivable, after Allowance for Credit Loss, Current $838,000 USD -13%
Assets, Current $2,531,000 USD -24%
Property, Plant and Equipment, Net $65,000 USD -52%
Operating Lease, Right-of-Use Asset $0 USD -100%
Assets $2,596,000 USD -29%
Accounts Payable, Current $3,955,000 USD 94%
Employee-related Liabilities, Current $223,000 USD -24%
Accrued Liabilities, Current $1,104,000 USD -11%
Contract with Customer, Liability, Current $0 USD -100%
Liabilities, Current $5,084,000 USD -14%
Liabilities $5,084,000 USD -14%
Retained Earnings (Accumulated Deficit) $358,561,000 USD -5.5%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $2,488,000 USD -7.7%
Liabilities and Equity $2,596,000 USD -29%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $4,632,000 USD 8.1%
Net Cash Provided by (Used in) Financing Activities $6,069,000 USD 200%
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares Authorized 100,000,000 shares 0%
Common Stock, Shares, Issued 2,676,642 shares 200%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,437,000 USD
Deferred Tax Assets, Valuation Allowance $115,487,000 USD 5.5%
Deferred Tax Assets, Gross $115,487,000 USD 5.5%
Operating Lease, Liability $14,961 USD -92%
Depreciation $94,000 USD -21%
Payments to Acquire Property, Plant, and Equipment $0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $18,634,000 USD 8%
Property, Plant and Equipment, Gross $7,250,000 USD 0.3%
Operating Lease, Liability, Current $0 USD -100%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $87 USD -99%
Deferred Tax Assets, Operating Loss Carryforwards $82,343,000 USD 4.9%
Preferred Stock, Shares Issued 10 shares
Preferred Stock, Shares Authorized 10,000,000 shares
Operating Lease, Payments $45,144 USD 0%
Preferred Stock, Shares Outstanding 10 shares
Share-based Payment Arrangement, Expense $341,000 USD -28%
Operating Leases, Future Minimum Payments Due $150,480 USD -0%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%